Table 1.
ARB monotherapy |
ACEI monotherapy |
|||
---|---|---|---|---|
Lumiracoxib 100 mg od (N = 57) | Ibuprofen 600 mg tid (N = 48) | Lumiracoxib 100 mg od (N = 42) | Ibuprofen 600 mg tid (N = 40) | |
Completed, n (%) | 53 (93.0) | 47 (97.9) | 39 (92.9) | 38 (95.0) |
Discontinued, n (%) | 4 (7.0) | 1 (2.1) | 3 (7.1) | 2 (5.0) |
Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Adverse event | 2 (3.5)* | 0 (0.0) | 1 (2.4)† | 0 (0.0) |
Unsatisfactory therapeutic effect | 1 (1.8) | 0 (0.0) | 1 (2.4) | 0 (0.0) |
Subject withdrew consent | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.0) |
Protocol violation | 1 (1.8) | 1 (2.1) | 0 (0.0) | 0 (0.0) |
Administrative problems | 0 (0.0) | 0 (0.0) | 1 (2.4) | 0 (0.0) |
Upper abdominal pain (n = 1), retinal detachment (n = 1).
Bells palsy (n = 1).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; od, once daily; tid, thrice daily.